Barry E. Greene
Independent DirectorMr. Barry E. Greene serves as Lead Independent Director at Karyopharm Therapeutics Inc. since January 2015. At the firm, he also served as Independent Director. He joined the firm in January 2013. He serves as Independent Director at Dyne Therapeutics, Inc. since June 22, 2026, as Independent Director at BCLS Acquisition Corp. since October 2020, as Independent Director at City Therapeutics, Inc. since September 2024 and as Member of the Strategic Advisory Board at Longwood Fund. He is a Senior Scholar at Duke University’s Medical School and Fuqua School of Business. Mr. Greene served as President, Chief Executive Officer & Director at Sage Therapeutics, Inc. from December 15, 2020 to July 31, 2025. At the company, he also served as Director from October 1, 2020 to December 15, 2020. He served as Independent Director at Acorda Therapeutics, Inc. from January 8, 2007 to August 20, 2021, where he served as a liaison between the Chief Executive Officer and Independent Directors. He served as Director at Greenlight Capital Re, Ltd. in 2020. He served as President at Alnylam Pharmaceuticals, Inc. from December 12, 2007 to October 1, 2020. At the company, he also served as Chief Operating Officer from October 2003 to September 19, 2016, as Principal Financial Officer, as Principal Accounting Officer and as Treasurer from February 2001 to September 2003. He was employed at Alnylam Pharmaceuticals, Inc. from February 2001 to October 1, 2020. He served as Director at Ambrx, Inc., which he joined in January 2014. He served as Director at Regulus Therapeutics Inc., where he was employed from January 2009 to November 5, 2012. He served as Director at Intercept Pharmaceuticals, Inc., where he was employed from February 8, 2011 to August 9, 2012. He served as Director at Regulus Therapeutics LLC, which he joined in November 2007. His prior experience includes serving as General Manager of Oncology at Millennium Pharmaceuticals Inc. from February 2001 to September 2003, where he led the global strategy and execution for its oncology business. He served as Executive Vice President and Chief Business Officer at Mediconsult.com from January 2000 to February 2001. He served as Vice President of Marketing and Customer Services and as Vice President of Strategic Integration at AstraZeneca from February 1997 to December 2001. He served as Partner at Andersen Consulting from 1986 to 1997, with leadership responsibility in the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene has experience in the healthcare, pharmaceutical and biotechnology industries. Mr. Greene received a B.S. in Industrial Engineering from the University of Pittsburgh.
Positions
- Company NameCity Therapeutics, Inc.Stock CodeCTYPositionIndependent DirectorColleagues
- JMJohn Michael MaraganoreCo-Founder & Executive Chair
- ACAndrew C. OrthPresident, CEO & Director
- TZTracy ZimmermannChief Scientific Officer
- BMBaisong MeiChief Medical Officer
- STSebastian TrousilCo-Founder & COO
- RMRon M. PhilipIndependent Director
- BEBarry E. GreeneIndependent Director
- SVSaraswathy V. NochurIndependent Director
- Company NameKaryopharm Therapeutics Inc.Stock CodeKPTIQPositionLead Independent DirectorColleagues
- RARichard A. PaulsonPresident, CEO & Director
- SPStuart PoultonExecutive VP & Chief Development Officer
- RRReshma RangwalaExecutive VP, Chief Medical Officer & Head of Research
- SSSharon ShachamCo-Founder & Chairman of Scientific Advisory Board
- LALori A. MacomberEVP, CFO & Treasurer
- DRDeepika Rachel PakianathanIndependent Director
- GGGaren G. BohlinIndependent Director
